JP2021535107A - Ｇｌａ遺伝子の突然変異を有する患者におけるファブリー病を治療する方法 - Google Patents

Ｇｌａ遺伝子の突然変異を有する患者におけるファブリー病を治療する方法 Download PDF

Info

Publication number
JP2021535107A
JP2021535107A JP2021509744A JP2021509744A JP2021535107A JP 2021535107 A JP2021535107 A JP 2021535107A JP 2021509744 A JP2021509744 A JP 2021509744A JP 2021509744 A JP2021509744 A JP 2021509744A JP 2021535107 A JP2021535107 A JP 2021535107A
Authority
JP
Japan
Prior art keywords
mutation
migalastat
patient
salt
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021509744A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021535107A5 (https=
Inventor
エルフリダ ベンジャミン，
Original Assignee
アミカス セラピューティックス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65279726&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2021535107(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アミカス セラピューティックス インコーポレイテッド filed Critical アミカス セラピューティックス インコーポレイテッド
Publication of JP2021535107A publication Critical patent/JP2021535107A/ja
Publication of JP2021535107A5 publication Critical patent/JP2021535107A5/ja
Priority to JP2023071652A priority Critical patent/JP7784398B2/ja
Priority to JP2025117816A priority patent/JP2025165955A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
JP2021509744A 2018-08-20 2019-01-16 Ｇｌａ遺伝子の突然変異を有する患者におけるファブリー病を治療する方法 Pending JP2021535107A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023071652A JP7784398B2 (ja) 2018-08-20 2023-04-25 Ｇｌａ遺伝子の突然変異を有する患者におけるファブリー病を治療する方法
JP2025117816A JP2025165955A (ja) 2018-08-20 2025-07-14 Ｇｌａ遺伝子の突然変異を有する患者におけるファブリー病を治療する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862719962P 2018-08-20 2018-08-20
US62/719,962 2018-08-20
PCT/US2019/013761 WO2020040806A1 (en) 2018-08-20 2019-01-16 Methods of treating fabry disease in patients having a mutation in the gla gene

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023071652A Division JP7784398B2 (ja) 2018-08-20 2023-04-25 Ｇｌａ遺伝子の突然変異を有する患者におけるファブリー病を治療する方法

Publications (2)

Publication Number Publication Date
JP2021535107A true JP2021535107A (ja) 2021-12-16
JP2021535107A5 JP2021535107A5 (https=) 2022-02-24

Family

ID=65279726

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021509744A Pending JP2021535107A (ja) 2018-08-20 2019-01-16 Ｇｌａ遺伝子の突然変異を有する患者におけるファブリー病を治療する方法
JP2023071652A Active JP7784398B2 (ja) 2018-08-20 2023-04-25 Ｇｌａ遺伝子の突然変異を有する患者におけるファブリー病を治療する方法
JP2025117816A Pending JP2025165955A (ja) 2018-08-20 2025-07-14 Ｇｌａ遺伝子の突然変異を有する患者におけるファブリー病を治療する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023071652A Active JP7784398B2 (ja) 2018-08-20 2023-04-25 Ｇｌａ遺伝子の突然変異を有する患者におけるファブリー病を治療する方法
JP2025117816A Pending JP2025165955A (ja) 2018-08-20 2025-07-14 Ｇｌａ遺伝子の突然変異を有する患者におけるファブリー病を治療する方法

Country Status (25)

Country Link
US (2) US12594268B2 (https=)
EP (7) EP3840753B1 (https=)
JP (3) JP2021535107A (https=)
KR (3) KR20240017127A (https=)
CN (1) CN112888439A (https=)
AU (2) AU2019326252A1 (https=)
BR (1) BR112021003137A2 (https=)
CA (1) CA3110065A1 (https=)
CL (3) CL2021000435A1 (https=)
DK (1) DK3840753T3 (https=)
EA (1) EA202190569A1 (https=)
ES (1) ES2993833T3 (https=)
FI (1) FI3840753T3 (https=)
HR (1) HRP20241454T1 (https=)
HU (1) HUE068783T2 (https=)
IL (2) IL325185A (https=)
LT (1) LT3840753T (https=)
MX (2) MX2021002070A (https=)
PL (1) PL3840753T3 (https=)
PT (1) PT3840753T (https=)
RS (1) RS66094B1 (https=)
SG (1) SG11202101117QA (https=)
SI (1) SI3840753T1 (https=)
SM (1) SMT202400436T1 (https=)
WO (1) WO2020040806A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2533050T6 (pl) 2006-05-16 2016-05-31 Amicus Therapeutics Inc Możliwości leczenia choroby Fabry'ego
EP2946785B1 (en) 2008-02-12 2018-10-24 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
CA3224546C (en) 2017-05-30 2026-02-24 Amicus Therapeutics, Inc. Use of migalastat in the treatment of fabry patients
KR20200128676A (ko) 2018-02-06 2020-11-16 아미쿠스 세라퓨틱스, 인코포레이티드 임신 환자의 파브리병 치료를 위한 미갈라스타트의 용도
US12594268B2 (en) 2018-08-20 2026-04-07 Amicus Therapeutics, Inc. Methods of treating Fabry disease in patients having a mutation in the GLA gene
KR20220044560A (ko) 2019-08-07 2022-04-08 아미쿠스 세라퓨틱스, 인코포레이티드 Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same
CN113969313A (zh) * 2021-11-29 2022-01-25 百世诺(北京)医学检验实验室有限公司 罕见遗传病突变基因及其应用
CN116656704B (zh) * 2023-06-01 2024-11-05 华东理工大学 用于治疗法布里病的转基因表达盒
CN116622750B (zh) * 2023-06-01 2024-05-31 上海勉亦生物科技有限公司 优化的人法布里转基因表达盒及其用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
SI2027137T1 (sl) 2005-06-08 2015-06-30 Amicus Therapeutics, Inc. Čiščenje imino in amino sladkorja
PL2533050T6 (pl) 2006-05-16 2016-05-31 Amicus Therapeutics Inc Możliwości leczenia choroby Fabry'ego
MX2009010557A (es) 2007-03-30 2009-11-19 Amicus Therapeutics Inc Metodo para el tratamiento de la enfermedad de fabry que utiliza chaperonas farmacologicas.
MX2009011473A (es) 2007-04-26 2010-01-18 Amicus Therapeutics Inc Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas.
US9999618B2 (en) 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
EP2946785B1 (en) 2008-02-12 2018-10-24 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
WO2010048532A1 (en) 2008-10-24 2010-04-29 Amicus Therapeutics, Inc. Multiple compartment dosing model
AU2010254092B2 (en) 2009-05-26 2015-11-12 Amicus Therapeutics, Inc. Utilization of pharmacological chaperones to improve manufacturing and purification of biologics
US9206457B2 (en) 2009-05-26 2015-12-08 Amicus Therapeutics, Inc. Utilization of pharmacological chaperones to improve manufacturing and purification of biologics
WO2011063048A2 (en) 2009-11-17 2011-05-26 Baylor Research Institute Urinary triaosylceramide (gb3) as a marker of cardiac disease
SG10201604757RA (en) * 2011-03-11 2016-08-30 Amicus Therapeutics Inc Dosing regimens for the treatment of fabry disease
US20120283290A1 (en) 2011-05-06 2012-11-08 Amicus Therapeutics Inc. Quantitation of gl3 in urine
KR102076585B1 (ko) 2011-12-22 2020-02-12 센토제너 아이피 게엠베하 리소좀 효소를 재배열하는 능력을 갖는 화합물 및 암브록솔 및/또는 암브록솔의 유도체의 조합물
US10155027B2 (en) 2012-07-17 2018-12-18 Amicus Therapeutics, Inc. Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease
WO2014014938A1 (en) 2012-07-17 2014-01-23 Amicus Therapeutics, Inc. Alpha-galactosidase a and 1-deoxygalactonojirimycin co-formulation
WO2014120900A1 (en) * 2013-01-31 2014-08-07 Icahn School Of Medicine At Mount Sinai Enhanced therapeutic regimens for treating fabry disease
US20170051267A1 (en) 2015-08-20 2017-02-23 Research Foundation Of The City University Of New York Novel alpha-galactosidase a derivatives
KR20190087673A (ko) * 2016-03-22 2019-07-24 아미쿠스 세라퓨틱스, 인코포레이티드 Ｇｌａ 유전자에 ｇ9331ａ 돌연변이를 갖는 환자에서 파브리 질병의 치료 방법
TW202408513A (zh) 2016-07-19 2024-03-01 美商阿米庫斯醫療股份有限公司 治療ert初治的和已經歷ert的患者中之法布瑞氏症
US11357834B2 (en) 2017-01-10 2022-06-14 Amicus Therapeutics, Inc. Recombinant α-galactosidase A for treatment of Fabry disease
CA3224546C (en) 2017-05-30 2026-02-24 Amicus Therapeutics, Inc. Use of migalastat in the treatment of fabry patients
SG11202000423XA (en) 2017-07-19 2020-02-27 Amicus Therapeutics Inc Treatment of fabry disease in ert-naïve and ert-experienced patients
US20200222377A1 (en) 2017-08-28 2020-07-16 Amicus Therapeutics, Inc. Methods Of Enhancing And/Or Stabilizing Cardiac Function In Patients With Fabry Disease
KR20200128676A (ko) 2018-02-06 2020-11-16 아미쿠스 세라퓨틱스, 인코포레이티드 임신 환자의 파브리병 치료를 위한 미갈라스타트의 용도
PT3749308T (pt) 2018-02-06 2024-01-25 Amicus Therapeutics Inc Tratamento de pacientes com doença de fabry clássica com migalastato
US12594268B2 (en) 2018-08-20 2026-04-07 Amicus Therapeutics, Inc. Methods of treating Fabry disease in patients having a mutation in the GLA gene
TW202042812A (zh) * 2019-01-22 2020-12-01 美商阿米庫斯醫療股份有限公司 減少法布瑞氏症患者中之腦血管事件之方法
MX2021015352A (es) 2019-06-11 2022-04-06 Amicus Therapeutics Inc Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal.
KR20220044560A (ko) 2019-08-07 2022-04-08 아미쿠스 세라퓨틱스, 인코포레이티드 Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법
KR20220150902A (ko) * 2020-02-10 2022-11-11 아미쿠스 세라퓨틱스, 인코포레이티드 파브리 질병을 치료하는 방법
AU2021230371A1 (en) * 2020-03-06 2022-09-29 Amicus Therapeutics, Inc. Methods of treating Fabry disease in patients having a mutation in the GLA gene

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BENJAMIN, ELFRIDA R: "The validation of pharmacogenetics for the identification of Fabry patients to be treated with migal", GENETICS IN MEDICINE, vol. 19, no. 4, JPN6022044785, 2017, pages 430 - 438, ISSN: 0005113950 *
LUKAS J: "Functional and Clinical Consequences of Novel α-Galactosidase A Mutations in Fabry Disease", HUM. MUTAT., vol. 37, no. 1, JPN6022044786, 2016, pages 43 - 51, ISSN: 0004905123 *

Also Published As

Publication number Publication date
CL2024000741A1 (es) 2024-10-04
SG11202101117QA (en) 2021-03-30
SMT202400436T1 (it) 2024-11-15
IL280961A (en) 2021-04-29
AU2019326252A1 (en) 2021-02-25
US20210315875A1 (en) 2021-10-14
FI3840753T3 (fi) 2024-10-30
EP4299117A3 (en) 2024-02-21
KR20210046729A (ko) 2021-04-28
ES2993833T3 (en) 2025-01-10
MX2024008350A (es) 2024-07-19
CL2024000739A1 (es) 2024-10-04
IL280961B1 (en) 2026-01-01
JP7784398B2 (ja) 2025-12-11
MX2021002070A (es) 2021-07-15
BR112021003137A2 (pt) 2021-05-11
EP4285990A2 (en) 2023-12-06
CN112888439A (zh) 2021-06-01
WO2020040806A1 (en) 2020-02-27
HRP20241454T1 (hr) 2024-12-20
JP2023106398A (ja) 2023-08-01
DK3840753T3 (da) 2024-10-28
JP2025165955A (ja) 2025-11-05
KR20240017128A (ko) 2024-02-06
EP4285991A2 (en) 2023-12-06
EP4289476A3 (en) 2024-02-21
EP4282472A2 (en) 2023-11-29
IL325185A (en) 2026-02-01
EP4289476A2 (en) 2023-12-13
EP4289475A2 (en) 2023-12-13
EP3840753B1 (en) 2024-07-24
KR20240017127A (ko) 2024-02-06
EP4285991A3 (en) 2024-02-21
LT3840753T (lt) 2024-11-11
PT3840753T (pt) 2024-10-30
CA3110065A1 (en) 2020-02-27
EP4289475A3 (en) 2024-02-21
EP4282472A3 (en) 2024-02-21
EP3840753A1 (en) 2021-06-30
US20240277687A1 (en) 2024-08-22
PL3840753T3 (pl) 2025-01-20
US12594268B2 (en) 2026-04-07
EP4299117A2 (en) 2024-01-03
EA202190569A1 (ru) 2021-06-01
CL2021000435A1 (es) 2021-10-22
HUE068783T2 (hu) 2025-01-28
EP4285990A3 (en) 2024-02-21
SI3840753T1 (sl) 2025-01-31
RS66094B1 (sr) 2024-11-29
AU2025205141A1 (en) 2025-07-31

Similar Documents

Publication Publication Date Title
JP2021535107A (ja) Ｇｌａ遺伝子の突然変異を有する患者におけるファブリー病を治療する方法
JP6788725B2 (ja) 腎機能障害を有するファブリー患者の治療方法
JP7098529B2 (ja) Ｇｌａ遺伝子にｇ９３３１ａ変異を有する患者においてファブリー病を処置する方法
JP7755929B2 (ja) ファブリー病患者における心臓機能の強化及び／または安定化方法
JP2022536687A (ja) 腎機能障害を有する患者のファブリー病を治療する方法
JP2021512896A (ja) 古典型ファブリー病患者の治療
JP7749572B2 (ja) Ｇｌａ遺伝子の突然変異を有する患者におけるファブリー病を治療する方法
JP7680356B2 (ja) ファブリー病患者の脳血管事象のリスク低減におけるミガロスタットの使用
JP2024525760A (ja) 小児患者のファブリー病を治療する方法
HK40104071A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
HK40105450A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
HK40104441A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
HK40104764A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
HK40104069A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
HK40122460A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
HK40057125B (en) Migalastat for use in methods of treating fabry disease in patients having a mutation in the gla gene
HK40057125A (en) Migalastat for use in methods of treating fabry disease in patients having a mutation in the gla gene

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20210517

A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20210517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220117

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221025

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230425

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250718